News Releases

Filter News Releases by year:
2023 | 2022 | 2021 | 2020 | 2019

30 Results

February 2023

Forgoing One Food Treats Eosinophilic Esophagitis as Well as Excluding Six

February 27, 2023

Eliminating animal milk alone from the diet of adults with eosinophilic esophagitis, or EoE, is as effective at treating the disease as eliminating animal milk plus five other common foods, a clinical trial funded by the National Institutes of Health has found. For people with EoE whose disease remains active after they forgo animal milk, a more restrictive diet may help them achieve remission, according to the researchers. These findings were published today in the journal The Lancet Gastroenterology & Hepatology

January 2023

NIH Study Links Specific Outdoor Air Pollutants to Asthma Attacks in Urban Children

January 4, 2023

Moderate levels of two outdoor air pollutants, ozone and fine particulate matter, are associated with non-viral asthma attacks in children and adolescents who live in low-income urban areas, a study funded by the National Institutes of Health has found. The study also identifies associations between exposure to the two pollutants and molecular changes in the children’s airways during non-viral asthma attacks, suggesting potential mechanisms for those attacks.

October 2022

Monoclonal Antibody Improves Cat Allergen Immunotherapy

October 11, 2022

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found. The findings were published Monday in the Journal of Allergy and Clinical Immunology

August 2022

Monoclonal Antibody Reduces Asthma Attacks in Urban Youth

August 10, 2022

A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found. This population has been underrepresented in previous clinical trials of asthma therapeutics. The findings were published today in the journal The Lancet.

June 2022

NIH Launches Trial of Monoclonal Antibody to Treat Asthma in Urban Youth

June 2, 2022

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods. The investigators also aim to define the activity levels of asthma-associated gene networks that correspond to specific health outcomes during antibody treatment in these children, most of whom are anticipated to be Black or Hispanic.

January 2022

Trial Tests Strategy to Augment Response to COVID-19 Vaccines in Transplant Recipients

January 31, 2022

A study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication. The clinical trial will enroll people for whom two to four doses of a COVID-19 mRNA vaccine did not elicit a detectable antibody response.

Oral Immunotherapy Induces Remission of Peanut Allergy in Some Young Children

January 20, 2022

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years. Remission was defined as being able to eat 5 grams of peanut protein, equivalent to 1.5 tablespoons of peanut butter, without having an allergic reaction six months after completing immunotherapy.

August 2021

NIH Launches Study of Extra COVID-19 Vaccine Dose in People with Autoimmune Disease

August 27, 2021

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population.

NIH Launches Study of Third COVID-19 Vaccine Dose in Kidney Transplant Recipients

August 10, 2021

A pilot study has begun to assess the antibody response to a third dose of an authorized COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

June 2021

Adjuvant Developed with NIH Funding Enhances Efficacy of India’s COVID-19 Vaccine

June 29, 2021

An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19. 

May 2021

Gene Therapy Restores Immune Function in Children with Rare Immunodeficiency

May 11, 2021

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.

NIH Statement on World Asthma Day 2021

May 5, 2021

On World Asthma Day, the National Institutes of Health reaffirms its commitment to research to improve the lives of people with asthma. More than 25 million people in the United States have asthma, including 5.1 million children, according to the Centers for Disease Control and Prevention. This chronic lung disease can reduce quality of life, contributes to considerable emotional and financial stress, and is a major contributing factor to missed time from school and work.

April 2021

NIH Establishes New Childhood Asthma Clinical Research Network

April 23, 2021

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE). This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop treatment and prevention approaches tailored to children of low-income families living in urban communities. NIAID intends to provide approximately $70 million over seven years to support the CAUSE network.

NIH Trial of Anti-CD14 Antibody to Treat COVID-19 Respiratory Disease Begins

April 13, 2021

A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

NIH Begins Study of Allergic Reactions to Moderna, Pfizer-BioNTech COVID-19 Vaccines

April 7, 2021

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of the body beyond the injection site. If such an allergic reaction occurs in study participants, investigators will assess whether the reactions are more frequent in participants who are highly allergic or have a mast cell disorder than in participants with no allergic history.

March 2021

NIH Study of Early Predictors, Mechanisms of Food Allergy and Eczema has Begun

March 19, 2021

A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun. The observational study of children from birth to age 3 years will examine the origins of allergic disease by integrating interdisciplinary analyses of data from more than 260 biological and environmental samples and survey responses from each of 2,500 families.

August 2020

NIH-Supported Scientists Demonstrate How Genetic Variations Cause Eczema

August 14, 2020

New NIH-supported research shows how two common variations in the KIF3A gene cause an impaired skin barrier that allows increased water loss from the skin.

July 2020

Kidney Transplantation Between People with HIV is Safe, NIH Study Finds

July 23, 2020

NIH Study finds that kidney transplantation between people with HIV is safe, making more kidneys available for those awaiting a transplant.

May 2020

NIH Statement on World Asthma Day 2020

May 5, 2020

On World Asthma Day, the NIH raises awareness about this disease, the people affected, and the biomedical research that improves prevention and treatment. 

Study to Determine Incidence of Novel Coronavirus Infection in U.S. Children Begins

May 4, 2020

A NIH study to determine the rate of novel coronavirus infection in children and family members in the United States has begun enrolling participants.

January 2020

New Multiple Sclerosis Treatment Trial Compares Stem Cell Transplantation to Best Available Drugs

January 7, 2020

A clinical trial has begun testing an experimental stem cell treatment against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will compare the safety, efficacy and cost-effectiveness of the two therapeutic approaches. 

September 2019

NIH Awards Contracts to Advance Tuberculosis Immunology Research

September 26, 2019

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $30 million in first-year funding to establish new centers for immunology research to accelerate progress in tuberculosis (TB) vaccine development. 

August 2019

NIH-Funded Study Will Test Seasonal Flu Vaccines With Two Experimental Adjuvants

August 8, 2019

An early-stage clinical trial is evaluating two licensed seasonal influenza vaccines, administered with or without novel adjuvants, for their safety and ability to generate an immune response. Adjuvants are compounds added to vaccines to induce stronger and longer-lasting immune responses. The Phase 1 study is enrolling healthy adult volunteers at eight sites across the United States. The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

June 2019

Immune Cells Play Unexpected Role in Early Tuberculosis Infection

June 5, 2019

A class of immune cells called innate lymphoid cells (ILCs) mediates the body’s initial defense against tuberculosis (TB), according to a report published online today in Nature. Boosting this response may provide a new approach to developing treatments and vaccines against TB, which causes more deaths worldwide than any other single infectious disease. The research was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health.

May 2019

Human Antibody Reveals Hidden Vulnerability in Influenza Virus

May 16, 2019

The ever-changing “head” of an influenza virus protein has an unexpected Achilles heel, report scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The team discovered and characterized the structure of a naturally occurring human antibody that recognizes and disrupts a portion of the hemagglutinin (HA) protein that the virus uses to enter and infect cells.